Avalyn Pharma Inc. (NASDAQ:AVLN – Get Free Report) has been given an average rating of “Moderate Buy” by the seven brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $59.20.
AVLN has been the topic of several analyst reports. Morgan Stanley lowered their target price on Avalyn Pharma from $57.00 to $53.00 and set an “overweight” rating on the stock in a research note on Monday. Wall Street Zen upgraded shares of Avalyn Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 14th. Weiss Ratings reissued a “sell (d+)” rating on shares of Avalyn Pharma in a research note on Wednesday, November 11th. Finally, Raymond James Financial initiated coverage on shares of Avalyn Pharma in a research report on Friday, October 2nd. They set an “outperform” rating and a $60.00 price objective for the company.
View Our Latest Stock Analysis on Avalyn Pharma
Insider Activity at Avalyn Pharma
In other Avalyn Pharma news, insider Howard Lazarus sold 13,300 shares of the business’s stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $27.90, for a total transaction of $371,070.00. Following the sale, the insider directly owned 13,300 shares in the company, valued at approximately $371,070. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Fmr Llc sold 53,454 shares of the firm’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $30.21, for a total transaction of $1,614,845.34. Following the completion of the sale, the insider owned 2,056,081 shares of the company’s stock, valued at $62,114,207.01. This trade represents a 2.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 241,754 shares of company stock valued at $7,073,165 over the last three months.
Hedge Funds Weigh In On Avalyn Pharma
Several hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. purchased a new stake in Avalyn Pharma during the third quarter worth $29,000. Manchester Capital Management LLC purchased a new position in shares of Avalyn Pharma in the third quarter valued at $36,000. Algert Global LLC purchased a new position in shares of Avalyn Pharma in the third quarter valued at $465,000. Profund Advisors LLC acquired a new position in shares of Avalyn Pharma during the 3rd quarter worth $668,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Avalyn Pharma during the 2nd quarter worth $1,321,000.
Avalyn Pharma Trading Up 3.6%
NASDAQ AVLN opened at $28.70 on Friday. The firm’s fifty day moving average price is $28.03 and its 200 day moving average price is $29.88. The company has a market capitalization of $1.28 billion and a price-to-earnings ratio of -1.22. Avalyn Pharma has a 12 month low of $22.24 and a 12 month high of $40.17. The company has a debt-to-equity ratio of 0.04, a current ratio of 25.76 and a quick ratio of 25.76.
Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.03). On average, sell-side analysts expect that Avalyn Pharma will post -3.87 earnings per share for the current fiscal year.
Avalyn Pharma Company Profile
Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.
Featured Stories
- Five stocks we like better than Avalyn Pharma
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
